The ARL8A Knockout HeLa Polyclonal Cells provide a pooled CRISPR/Cas9-edited HeLa cell population with targeted disruption of the ARL8A gene, resulting in a heterogeneous loss-of-function model for the lysosomal small GTPase ARL8A. This polyclonal knockout cell population is generated using CRISPR/Cas9-mediated gene disruption, offering a versatile tool for investigating ARL8A-dependent processes without the clonal selection biases of monoclonal lines. The cells are supplied as a mixed polyclonal pool, representing diverse editing outcomes that collectively abrogate ARL8A function.
HeLa cells, derived from a cervical adenocarcinoma, constitute a widely studied human epithelial cell line that is positive for human papillomavirus 18 (HPV18) and originates from a female donor. These cells are renowned for their robust proliferation, genetic stability under standard culture conditions, and extensive use as a model for cancer biology, particularly in the study of cell motility, invasion, and organelle trafficking. Their well-characterized cytoskeletal architecture and active endolysosomal system make HeLa cells an ideal host for studying the role of ARL8A in lysosome positioning and autophagy.
ARL8A encodes a small GTPase that cycles between GTP- and GDP-bound states to control microtubule-dependent transport of lysosomes and late endosomes. In the active state, it recruits SKIP/PLEKHM2, bridging lysosomes to kinesin-1 (KIF5B) for anterograde movement. GDP-ARL8A favors dynein-mediated retrograde transport, leading to perinuclear clustering. Activation is regulated by the BORC complex and upstream signals such as mTORC1 and amino acid sensing. ARL8A interacts with VPS41, RAB7A, and LAMP1/2, linking transport to lysosome fusion and degradation. It also regulates autophagic flux and mTORC1 signaling by modulating lysosome availability and positioning.
In HeLa cells, ARL8A knockout profoundly alters lysosome distribution, causing perinuclear accumulation and impaired peripheral trafficking. This redistribution affects cell migration and invasion, as lysosome exocytosis and focal adhesion turnover are compromised. Because HeLa cells are a classic metastasis model, this knockout enables dissection of how lysosome positioning drives invasive behaviour. Disrupted lysosome motility also impairs autophagic degradation and mTORC1 reactivation, linking nutrient sensing to organelle dynamics and malignancy. The polyclonal nature further permits analysis of phenotypic variability and compensatory mechanisms.
This product enables a broad range of research applications, including immunofluorescence microscopy to visualize lysosome distribution, live-cell imaging to track lysosome motility, and biochemical assays such as western blotting for autophagy markers LC3 and p62 to assess autophagic flux. Researchers can employ matrigel invasion assays to evaluate metastatic potential, co-immunoprecipitation to probe ARL8A?CSKIP interactions, and GTPase activity measurements to study regulatory mechanisms. Additionally, the cells are suitable for drug screening studies targeting lysosomotropic agents or modulators of mTOR signaling. For further information, please contact Ascent Research.
